FBXO30 and neoplasm: In mPCa patients with low tumor volume, methylated ctDNA was detected in a total of 32.3% (10/31) of the patients, with 6/31 (19.4%) patients positive for DOCK2, 9/31 (29.0%) positive for HAPLN3, and 3/12 (25.0%) positive for FBXO30 (Figure 5A–C).